Importantly, miR-29a/b target ten–eleven translocation 2 (TET2), an enzyme that catalyzes the oxidation of methylated cytosine (5-mC) to 5-hydroxymethylated cytosine (5-hmC), an epigenetic hallmark of prostate cancer progression [91]. Here, TET2 is linked to prostate carcinoma.